
Conference Coverage
Latest Content

Dana-Farber Expert Explains Rina-S Data in Platinum-Resistant Ovarian Cancer

Aspirin Did Not Prevent Colorectal Cancer Return After Liver Metastasis Treatment

The Cancer Search Bar: Top Lung Cancer Surgery Questions Answered

Life After Cancer: Challenge Yourself to Build Healthier Habits and Stronger Relationships

Rina-S Shows 45.9% Response Rate in Platinum-Resistant Ovarian Cancer

Shorts










Videos
All News

The FDA withdrew Zepzelca’s accelerated approval for small cell lung cancer after the LAGOON trial failed to show longer survival. Its maintenance use with Tecentriq is unaffected.

Prostate cancer grows slowly, and while 50% of men on active surveillance eventually need treatment, waiting can mean years without side effects.

Liver and bile duct cancer treatment has changed quickly since 2021, with new immunotherapy combinations, targeted pills and a new radiation option. Here's what's been approved and what it means for patients.

Tecentriq plus chemotherapy lowered the risk of cancer returning or death by 50% versus chemotherapy alone in patients with stage 3 dMMR colon cancer.

In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.

In a Johns Hopkins study, 64% of African American patients with myeloma received bone-modifying drugs in their first year, compared with 77% of White patients.

ASTRO’s first bladder cancer radiation guideline supports trimodal therapy as an alternative to bladder removal for select patients with muscle-invasive disease.

The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.

Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.

In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.

Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.

In a study of more than 250,000 older adults presented at ASTRO 2026, people with depression who started talk therapy within a week of their cancer diagnosis had a 27% lower risk of dying from their cancer. But most people with depression received no mental health treatment at all.

Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.

Living with incurable small lymphocytic lymphoma means facing new health challenges and fears while finding a balance between caution, optimism and daily life.






























